Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.69
Peer-review started: July 4, 2020
First decision: August 8, 2020
Revised: August 15, 2020
Accepted: November 12, 2020
Article in press: November 12, 2020
Published online: January 7, 2021
Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) is widely used to treat pancreatic cancer-associated pain.
Response to the treatment of EUS-CPN is variable.
To explore determinants of pain response in EUS-CPN for pancreatic cancer-associated pain.
Univariable and multivariable logistic regression analyses were performed to explore predictors of pain response.
Invisible ganglia, metastatic disease, and invasion of the celiac plexus were identified as significant factors for a negative response to EUS-CPN. No severe adverse events were reported.
Invisible ganglia, distant metastasis, and invasion of the celiac plexus were predictors of less effective response in EUS-CPN for pancreatic cancer-related pain. For these patients, attention should be given regarding efficacy.
These findings could be helpful to endoscopists or oncologists to develop an appropriate treatment scheme for pain management in pancreatic cancer patients.